Abstract
Cardiovascular disease (CVD) remains the largest cause of diabetes-related morbidity and mortality (1,2), yet the current understanding of the global prevalence of diabetes-related complications, including CVD, is still limited (3). The CAPTURE study estimated the prevalence of established CVD and its management in adults with type 2 diabetes across 13 countries using standardized methodology.
The Czech Republic was one of the included countries with 400 enrolled participants. In the Czech Republic, one of the four participants had established CVD with a weighted CVD prevalence estimate at 22.8% [18.8-26.7%] 95% CI.
Most cases of CVD were atherosclerotic (76.6%), with the weighted ASCVD prevalence estimated at 17.5% [13.9-21.1%]95% CI. One of the secondary objectives of the CAPTURE study was to further characterize the study population regarding GLAs (blood glucose-lowering agents) usage with reference to GLP-1 RAs and SGLT2is with demonstrated CV benefit.
In the Czech Republic, 16.8% of participants in total were prescribed a GLA with demonstrated CV benefit. Treatment with GLA with CV benefit was present more in the CVD group than the non-CVD group (24.2% vs 14.6%).
SGLT2is were used more frequently than GLP-1 RAs (10.5% vs 6.3%) in the study population with a higher use of both therapeutic classes in the CVD group. The low occurrence of treatment with GLAs with CV benefit even in participants with established CVD suggests that most participants were not managed according to contemporary diabetes and cardiology guidelines.